Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. AbbVie Inc.
EIR
•AbbVie Inc.•December 15, 2017

AbbVie Inc. – FDA EIR, Dec 15, 2017

Record Details

An FDA inspection of AbbVie Inc.'s North Chicago, IL facility was conducted from November 27 to December 15, 2017. This was a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI), focusing on finished dosage drug manufacturing, including Imbruvica® Ibrutinib, Duopa, Humira, and Ultane (Sevoflurane). The inspection covered various systems such as quality, packaging and labeling, laboratory, facilities and equipment, materials, and production.

The inspection concluded with the issuance of a four-item FDA Form 483, detailing observations of objectionable conditions, alongside three additional discussion points for management. Key issues identified included inadequate investigation into a 24-month stability failure for fill weight in Sevoflurane, and a failure to utilize Annual Product Review feedback to address recurring "low fill" complaints for the same product proactively. Deficiencies in quality system documentation were noted, specifically the omission of historical data in complaint investigations related to serious adverse events for Humira. Furthermore, packaging operations showed weaknesses, such as a lack of standard operating procedures and documentation for in-process quality inspections, and an instance of inadequate line clearance resulting in a potential product mix-up. The firm also lacked an established schedule for periodic revalidation reviews of equipment. AbbVie Inc. is required to address these observations with comprehensive corrective and preventive actions to ensure compliance with regulatory standards. Notably, the Imbruvica® Ibrutinib tablet, NDA 210563, was recommended for approval despite these findings.

Company
AbbVie Inc.
Inspection date
December 15, 2017
Product type
drugs
Office
Chicago District Office
People
  • Chad Ballard (company_representative)
  • Scott Page (company_representative)
  • Walter Routh (company_representative)
  • Russell K. Riley (Investigator)
  • Amy A. Johnson
View Company Profile

ID · 670afc69-446b-472a-b6de-83d020c0613a

Violation Codes3
21 CFR 820.19821 CFR 820.10021 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for AbbVie Inc.
  • 483 - 2023-01-31January 31, 2023
  • EIR - 2021-12-15December 15, 2021
  • EIR - 2019-02-15February 15, 2019
  • EIR - 2018-07-02July 2, 2018
  • 483 - 2018-07-02July 2, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AbbVie Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.